Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
Key Highlights
- ➤14 na-SPMS patients dosed; all improved or remained stable within six months
- ➤INFORM-MS Phase 2a trial evaluates intranasal foralumab in non-active SPMS
- ➤Management team attending MSToronto2026 to discuss clinical programs and partnerships
- ➤Foralumab is the only fully human anti-CD3 mAb currently in clinical development
Expert Statements
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences
“We are pleased to attend and participate in MSToronto2026, one of the most important gatherings in the MS research community”
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences
“This meeting provides an excellent opportunity to engage with key opinion leaders, investigators, and potential partners as we advance intranasal foralumab, our novel fully human anti-CD3 monoclonal antibody designed to induce regulatory T cells and reduce microglial activation in neuroinflammatory and neurodegenerative diseases.”
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that members of its management and business development team will attend the 10th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, known as MSToronto2026, being held October 21–23, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. The joint ACTRIMS-ECTRIMS meeting is a premier international scientific forum uniting researchers, clinicians, and industry leaders focused on advances in multiple sclerosis (MS) and related neuroinflammatory disorders.
Get started
Create a free account to read the full story.